Valuation: BioTime, Inc.

Market Cap 246M 219M 203M 184M 346M 23.31B 351M 2.44B 956M 12.19B 923M 903M 38.93B P/E 2026 *
-16.2x
P/E 2027 * -7.58x
Enterprise Value 246M 219M 203M 184M 346M 23.31B 351M 2.44B 956M 12.19B 923M 903M 38.93B EV / Sales 2026 *
16.2x
EV / Sales 2027 * 14.6x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+7.37%-11.55% - - 241M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +3.53%+0.51%+52.90%+121.07% 41.76B
Weighted average by Cap. +3.05%+0.62%+51.69%+122.72%

Financials

2026 *2027 *
Net sales 15.19M 13.53M 12.54M 11.36M 21.37M 1.44B 21.67M 151M 59.06M 753M 56.99M 55.8M 2.4B 16.83M 14.99M 13.9M 12.59M 23.67M 1.6B 24.02M 167M 65.45M 834M 63.14M 61.83M 2.66B
Net income -22.64M -20.16M -18.69M -16.93M -31.84M -2.15B -32.3M -224M -88.02M -1.12B -84.92M -83.15M -3.58B -34.44M -30.67M -28.43M -25.75M -48.43M -3.26B -49.13M -341M -134M -1.71B -129M -126M -5.45B
Net Debt - -
Logo BioTime, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - BioTime, Inc.